Shots:
- NKGen Biotech has partnered with HekaBio to accelerate the regulatory, manufacturing & commercial development of troculeucel in Japan
- As per the collaboration, HekaBio will lead trials & handle regulatory activities with Japan’s PMDA for pre-market approval of troculeucel in neurodegenerative diseases, incl. Alzheimer’s & Parkinson’s. Also, HekaBio aims for first pts dosing in Japan within the next 12mos.
- Troculeucel is a patient-specific, ex vivo expanded autologous NK cell immunotherapy that is being developed by NKGen for the treatment of neurodegenerative disorders & a wide range of cancers
Ref: Globenewswire | Image: NKGen Biotech & Hekabio| Press Release
Related News:- Bio-Thera Reports the US FDA’s BLA Acceptance of BAT2506 (Biosimilar, Simponi)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
